These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32129681)

  • 1. Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy.
    Tantry U; Cummings C; Mackrell P; Gonze M; Ulloa K; Bafford R; Rout A; Sukhi A; Gurbel P
    Future Cardiol; 2020 Mar; 16(2):69-75. PubMed ID: 32129681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?
    Kruger PC; Guzik TJ; Eikelboom JW
    Kardiol Pol; 2019 Aug; 77(7-8):661-669. PubMed ID: 31144674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
    Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
    Branch KR; Probstfield JL; Eikelboom JW; Bosch J; Maggioni AP; Cheng RK; Bhatt DL; Avezum A; Fox KAA; Connolly SJ; Shestakovska O; Yusuf S
    Circulation; 2019 Aug; 140(7):529-537. PubMed ID: 31163978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD.
    Morrison JT; Canonico ME; Anand SS; Patel MR; Debus ES; Nehler MR; Hess CN; Hsia J; Capell WH; Muehlhofer E; Haskell LP; Berkowitz SD; Bauersachs RM; Bonaca MP
    Circulation; 2024 May; 149(19):1536-1539. PubMed ID: 38709838
    [No Abstract]   [Full Text] [Related]  

  • 6. Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease.
    Wheeler M; Chan N; Eikelboom J
    Future Cardiol; 2020 Nov; 16(6):597-611. PubMed ID: 32633570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban in Peripheral Artery Disease after Revascularization.
    Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
    N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis.
    Russo V; Fabiani D; Leonardi S; Attena E; D'Alterio G; Cotticelli C; Rago A; Sarpa S; Maione B; D'Onofrio A; Golino P; Nigro G
    J Cardiovasc Pharmacol; 2023 Feb; 81(2):129-133. PubMed ID: 36607629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
    Coppens M; Weitz JI; Eikelboom JWA
    Circ Res; 2019 Feb; 124(3):416-425. PubMed ID: 30702997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease.
    Coleman CI; Kharat AA; Bookhart B; Baker WL
    Curr Med Res Opin; 2022 Jan; 38(1):27-34. PubMed ID: 34641745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
    Liang Y; Zhu J; Liu L; Anand SS; Connolly SJ; Bosch J; Guzik TJ; O'Donnell M; Dagenais GR; Fox KA; Shestakovska O; Berkowitz SD; Muehlhofer E; Keller L; Yusuf S; Eikelboom JW;
    Cardiovasc Res; 2021 Feb; 117(3):942-949. PubMed ID: 32289159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
    Kaplovitch E; Eikelboom JW; Dyal L; Aboyans V; Abola MT; Verhamme P; Avezum A; Fox KAA; Berkowitz SD; Bangdiwala SI; Yusuf S; Anand SS
    JAMA Cardiol; 2021 Jan; 6(1):21-29. PubMed ID: 32997098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
    Lapébie FX; Aboyans V; Lacroix P; Constans J; Boulon C; Messas E; Ferrières J; Bongard V; Bura-Rivière A
    Eur J Vasc Endovasc Surg; 2021 Sep; 62(3):439-449. PubMed ID: 34330647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition.
    Ramacciotti E; Weitz JI
    Thromb Res; 2019 Dec; 184():44-49. PubMed ID: 31706067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease.
    Gibler WB
    Crit Pathw Cardiol; 2018 Jun; 17(2):53-68. PubMed ID: 29768312
    [No Abstract]   [Full Text] [Related]  

  • 16. Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial.
    Ramacciotti E; Agati LB; Volpiani GG; Brito KF; Ribeiro CM; Aguiar VCR; Ramacciotti LS; Paganotti A; Pereira FM; Caffaro RA; Fioranelli A; Krakauer R; Rached HRS; Wolosker N; Anand SS; Eikelboom JW; Lopes RD
    Clin Appl Thromb Hemost; 2022; 28():10760296211073922. PubMed ID: 35043716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers.
    Pistrosch F; Matschke JB; Schipp D; Schipp B; Henkel E; Weigmann I; Sradnick J; Bornstein SR; Birkenfeld AL; Hanefeld M
    Diabetologia; 2021 Dec; 64(12):2701-2712. PubMed ID: 34495376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS.
    Bhagirath VC; Eikelboom JW; Anand SS
    Future Cardiol; 2018 Nov; 14(6):443-453. PubMed ID: 30417662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin.
    Eikelboom JW; Bosch JJ; Connolly SJ; Shestakovska O; Dagenais GR; Hart RG; Leong DP; O'Donnell M; Fox KAA; Bhatt DL; Cairns JA; Tasto C; Berkowitz SD; Cook Bruns N; Muehlhofer E; Diaz R; Maggioni AP; Yusuf S
    J Am Coll Cardiol; 2019 Sep; 74(12):1519-1528. PubMed ID: 31537259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.